Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

Maureen Offiah, MD, is a board-certified dermatologist at Hattiesburg Clinic in Mississippi.

Articles

Maureen Offiah, MD, reflected on the key takeaways as an attendee at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

A Clinician’s Perspective of RAD 2025: Part 1

Hershel Dobkin, MD, is a board-certified dermatologist based in Bexley, Ohio, specializing in both medical and surgical dermatology. Dobkin treats patients of all ages with special interest in skin cancer detection and treatment, nail surgery, acne, eczema, psoriasis, hair loss, autoimmune skin diseases and skin infections.

In celebration of Men's Health Month, Hershel Dobkin, MD, FAAD, shed some light on a "taboo" topic.

It's Not Genital Warts: A Clinician's Guide to Reassuring Men's Genital Concerns

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

In a real-world study, the combination of Cuticapil stem hair serum and minoxidil  reduced shedding and improved hair density.

Novel Stem Hair Serum Improves Hair Loss When Combined with Minoxidil

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the first day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

Clinical Pearls from the 2025 Fall Clinical PA/NP Meeting: Day 1

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

In this article, Drs. Lawrence Eichenfield and Jessica Sprague review some of the most significant findings and developments in pediatric dermatology from the last year beginning with the availability of biologic agents for pediatric psoriasis and atopic dermatitis.

Pediatric dermatology updates

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

, Amanda Caldwell, MSN, APRN-C, a dermatology nurse practitioner at US Dermatology Partners and newly inducted president of the 

Society for Dermatology Nurse Practitioners (SDNP),

 shared her commitment to expanding support and educational resources for dermatology NPs and PAs through the revamped SDNP.

Amanda Caldwell, MSN, APRN-C, is fostering community and collaboration for NPs and PAs as the new president of the SDNP.

SDNP President Amanda Caldwell, MSN, APRN-C, on Empowering NPs Through Enhanced Support and Education

Caldwell is enthusiastic about increasing NP engagement in research and education through SDNP. The organization is actively developing partnerships with journals to help members navigate the process of publishing. With a dedicated team behind her, she encourages NPs to reach out and share their goals, interests, and dreams so the organization can provide guidance. In addition to research, SDNP is building out educational tools, including resources on textbooks, apps, and continuing education opportunities. A key initiative under her leadership is to modernize and humanize SDNP, emphasizing accessibility through social media, peer support, and a stronger digital presence.

She also highlights the welcoming, supportive nature of SDNP, especially for those who are unfamiliar with the organization and are considering getting involved. Having discovered SDNP only 3 years ago, Caldwell recalled how attending her first SDNP conference as an introverted newcomer inspired her to become a volunteer.

“I felt welcomed and at home. And I met so many wonderful people across the whole US that I keep in touch with,” she said. “And so instantly after that conference, I felt really empowered and said, ‘OK, I'm ready to change the world. What can I do?’”

Importantly, Caldwell emphasized that SDNP isn’t just for members. Free monthly webinars, open conference access, and strong interprofessional collaboration, including support from physicians, make the organization a valuable resource for NPs and PAs of any level. She believes that thanks to their nursing background, NPs bring a holistic, patient-centered approach to dermatology, which is particularly essential in underserved areas. Caldwell recognizes this and invites all NPs to get involved, take advantage of the resources, and find an empowered community of peers through SDNP.

“It's contagious, it's infectious, and so if you just give it a chance and see, I think we would have everyone hooked,” Caldwell concluded.

Amanda Caldwell, MSN, APRN-C, aims to enhance support and educational resources for dermatology nurse practitioners (NPs) and physician assistants (PAs) through the Society for Dermatology Nurse Practitioners (SDNP). Her initiatives focus on increasing NP engagement in research, modernizing SDNP's digital presence, and fostering a welcoming community. SDNP offers free webinars, open conference access, and interprofessional collaboration, making it a valuable resource for NPs and PAs. Caldwell emphasizes the holistic, patient-centered approach NPs bring to dermatology, especially in underserved areas, and encourages involvement in SDNP.

Amanda Caldwell, MSN, APRN-C, is promoting accessibility, education, and relatability as the newly inducted president of the Society for Dermatology Nurse Practitioners.

From Patient to President: Amanda Caldwell, MSN, APRN-C, And Her Journey with SDNP

Amanda Caldwell, MSN, APRN-C, a dermatology nurse practitioner at US Dermatology Partners, has recently stepped into her role as president of the 

Society for Dermatology Nurse Practitioners (SDNP)

. With a passion for accessible health care and general dermatology, Caldwell brings both personal and professional motivation to her leadership. Having battled skin cancer at age 23, along with other dermatological conditions, her early experience with the specialty drove her commitment to dermatologic care. Caldwell’s vision as president centers on expanding access to high-quality education and career support, not just for nurse practitioners (NPs) but for physician assistants (PAs) as well.

“We're continuing to grow, and I want to be the home for NP dermatology practitioners, but also, we welcome our physician assistant friends too...we’re stronger together,” she emphasized.

Her team’s initiatives include offering free monthly webinars, comprehensive review courses, and new member engagement efforts as part of an SDNP rebrand. She is especially focused on listening to member needs and filling the gaps in the industry, whether it's helping find jobs, working with collaborators, or navigating practice authority.

Caldwell credits much of her professional growth to mentorship, particularly from Christy Parham, MD, MPH, MA, who encouraged her to become a provider, and Mark Fleischman, MD, FAAD, her collaborator at US Dermatology Partners. On a personal level, her mother remains a key source of inspiration. After the sudden loss of Caldwell’s father when she was 12 years old, her mother worked full time and earned a college degree while raising four children, instilling resilience and purpose in Caldwell’s journey.

Among the top issues facing dermatology NPs today, Caldwell identifies limited access to education, unequal pay, and difficulty finding employment in the specialty. She advocates for equal compensation, noting that many NPs practice independently in full practice authority states and manage complex conditions such as autoimmune diseases. Caldwell also aims to boost SDNP’s networking power to connect NPs with job opportunities. Through her leadership, SDNP hopes to reduce barriers and foster professional growth in dermatologic practice.

Above all, she is focused on building a supportive, inclusive home for dermatology NPs and PAs.
“To me, especially with patients and even myself, I think being relatable is important,” Caldwell said. “We're in this world together. Let's help each other out, and if someone knows I've kind of walked in their shoes, it definitely helps build some trust.”

Amanda Caldwell, MSN, APRN-C, has assumed the presidency of the Society for Dermatology Nurse Practitioners (SDNP), driven by her personal and professional experiences in dermatology. Her leadership aims to enhance access to education and career support for nurse practitioners (NPs) and physician assistants (PAs). Initiatives include free webinars, review courses, and member engagement efforts. Caldwell emphasizes mentorship and aims to address challenges like limited education access, unequal pay, and employment difficulties. Her vision is to create a supportive, inclusive community for dermatology NPs and PAs.

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

Polls 

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

Barzolvolimab (CDX-0159) demonstrated rapid symptom reduction in a recent study exploring its efficacy in adult patients with moderate to severe antihistamine-refractory chronic spontaneous urticaria (CSU). 

European Journal of Allergy and Clinical Immunology

 reported high percentages of patients achieving well-controlled and complete responses after treatment with the monoclonal anti-KIT antibody vs placebo.

reported that barzolvolimab reduced disease activity and skin mast cells in patients with chronic inducible urticaria.

The first-in-class anti-KIT mAb has also demonstrated improvements in itch and circulating tryptase, leading researchers to examine its effectiveness in CSU, as well.

Researchers conducted a phase 1b, double-blinded, randomized study (

) evaluating the safety, pharmacokinetics, and pharmacodynamics of barzolvolimab.

 Participants were assigned to receive barzolvolimab or placebo on 1 of 2 dosing schedules: every 4 or 8 weeks. The study included a 2-week screening phase, 12 weeks of treatment, and a 12-week follow-up.

A total of 93.3% (n=42) of patients completed the 12-week treatment phase. The demographic and disease characteristics were balanced across all study arms, with most participants classified as having severe CSU at baseline. Among barzolvolimab-treated patients (n=35), the median age was 49.3 years, and 80% were women. Duration of CSU varied widely, from as little as 0.6 years to more than 6 decades.

Barzolvolimab demonstrated robust and sustained suppression of serum tryptase. Within days of the initial dose, tryptase levels dropped by more than 90% in the 1.5-mg/kg and higher-dose cohorts and remained suppressed throughout the 12-week dosing period.

Clinically meaningful reductions in disease severity were observed in barzolvolimab-treated patients across all cohorts. By week 12, average UAS7 scores declined substantially, with the 3.0-mg/kg and 4.5-mg/kg groups experiencing reductions of 30 to 35 points compared with baseline. In contrast, placebo-treated patients showed minimal change.

A significant proportion of patients receiving 3.0-mg/kg and 4.5-mg/kg barzolvolimab achieved near-complete or complete symptom control. More than 60% of patients in the highest-dose group reached UAS7 scores below 6 by the end of the treatment period. These rates were notably higher than in placebo recipients, none of whom reached full disease control.

Barzolvolimab was generally well-tolerated, with adverse events being mostly mild to moderate in severity. There was no reported indication of cumulative toxicity or worsening safety profile with ascending dose.

"For patients with severe CSU, symptom control can be difficult to attain with available therapies," the study authors wrote. "This study initially characterizes barzolvolimab as a promising novel treatment in antihistamine-refractory CSU."

The study may have been limited by the small sample size of patients and variation in drugs used prior to the study. Moving forward, researchers noted the importance of larger-scale studies of barzolvolimab in chronic inducible urticaria, of which studies of this nature are ongoing.

Maurer M, Metz M, Anderson J, et al. Anti-KIT barzolvolimab for chronic spontaneous urticaria. 

Terhorst-Molawi D, Hawro T, Grekowitz E, et al. Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. 

A study of CDX-0159 in patients with chronic spontaneous urticaria. ClinicalTrials.gov. NCT04538794. Updated July 19, 2023. Accessed June 9, 2025. 

https://clinicaltrials.gov/study/NCT04538794?term=NCT04538794&rank=1

Barzolvolimab (CDX-0159) has shown promising results in reducing symptoms in patients with moderate to severe antihistamine-refractory chronic spontaneous urticaria (CSU). In a phase 1b study, barzolvolimab demonstrated significant suppression of serum tryptase and substantial reductions in disease severity, with many patients achieving near-complete symptom control. The treatment was well-tolerated, with mostly mild to moderate adverse events. Despite the study's small sample size, these findings suggest barzolvolimab as a potential novel treatment for severe CSU, warranting further investigation in larger-scale studies.

The monoclonal anti-KIT antibody exhibited promise in adults with moderate to severe antihistamine-refractory CSU.

Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria

 conference in Nashville, Tennessee, Eli Lilly and Company shared final results from the phase 3b ADmirable trial of lebrikizumab (Ebglyss).

This is the first study to evaluate lebrikizumab’s effectiveness and safety in adult and adolescent patients with pigmented skin and atopic dermatitis (AD), as this population is typically underrepresented in clinical trials.

) included 90 patients 12 years and older (weight: ≥ 40 kg) with moderate to severe AD and pigmented skin, according to the Fitzpatrick skin type scale (IV, V, or VI). Participants self-identified as Black or African American, Asian, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander. The mean age of patients was 40.7 years. Approximately 43.3% of participants had a Fitzpatrick skin phototype of IV.

"Skin pigmentation matters in evaluating patients with atopic dermatitis, because from a medical perspective, the disease presents differently in darker skin tones vs lighter (eg, redness can be more subtle, pigmentation more prominent, and diagnosis and evaluation more challenging). Additionally, in the next 20 years, people who identify as American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian, or other Pacific Islander are projected to represent more than half of all Americans, which drives our urgency to invest in clinical research that helps address longstanding medical gaps in these populations. ADmirable is the first dedicated study to evaluate the efficacy and safety of Ebglyss in adult and adolescent patients with AD in these patients frequently underrepresented in clinical trials," said Anabela Cardoso, MD, senior vice president of immunology medical affairs at Eli Lilly and Company, in an interview with 

The patients received lebrikizumab 250 mg (500-mg loading dose at baseline and week 2) subcutaneously every 2 weeks for 16 weeks. Then, from weeks 16 to 24, those who responded to treatment received lebrikizumab 250 mg once every 4 weeks; those with inadequate response continued with the dosage every 2 weeks.

Respondents were defined as having an Investigator’s Global Assessment score of 0 or 1 with a 2-point or greater improvement (IGA 0/1) or 75% or greater improvement in Eczema Area and Severity Index (EASI 75). The primary end point of the study was achieving an EASI score of 75 at week 16. Secondary end points revolved around safety and efficacy using PDCA Derm, assessing cutaneous postinflammatory hyperpigmentation and hypopigmentation.

Approximately 68.9% of patients began the trial with moderate disease (IGA = 3) with a mean EASI of 26.4 and an average Pruritus Numeric Rating Scale (NRS) score of 7. At week 16, EASI 75, EASI 90, and IGA 0/1 were achieved by 69.2%, 44.9%, and 44.9% of patients, respectively. This includes more than 88% of patients with the darkest skin tones (Fitzpatrick V and VI). Approximately 73% of respondents were able to switch to a once-monthly maintenance dose after 16 weeks.

Nearly 60% of patients observed a 4-point or greater improvement in Pruritus NRS. These numbers increased at week 24 with EASI 75, EASI 90, and IGA 0/1 achieved by 78.4%, 47.3%, and 54.1% of patients, respectively. Moreover, 61.5% of participants had a 4-point or greater Pruritus NRS improvement.

Additionally, 4-point or greater improvements in the Dermatology Life Quality Index were reached by 71.7% and 72.9% of patients at weeks 16 and 24, respectively. More than 64% of patients with hyperpigmented lesions and 25% with hypopigmented lesions showed improvement after 24 weeks. Most treatment-emergent adverse effects were mild or moderate, with only 1 reported case of conjunctivitis and injection site reaction. None of the adverse events were serious, and the drug did not need to be discontinued. This safety profile is consistent with previous long-term trials of lebrikizumab, regardless of dosage and frequency.

Overall, patients with skin of color and moderate to severe AD severity responded well to lebrikizumab after 24 weeks, with improvements in symptoms such as itch and hyperpigmentation. Response was noted as early as week 16 and continued to improve throughout the trial with a favorable safety profile.

"These new, 24-week data from ADmirable—the first dedicated study for evaluating the efficacy and safety of Ebglyss in adult and adolescent patients with pigmented skin and moderate-to-severe atopic dermatitis—reinforce the efficacy and safety of Ebglyss as a first-line biologic, following prescription topicals, with once-monthly maintenance dosing after the 4-month initial dosing for adults and adolescents, regardless of skin tone. These add to the robust and extensive data supporting Ebglyss's value for a broad range of patients with moderate to severe atopic dermatitis," Cardoso concluded.

1. Alexis A, Moiin A, Waibel J, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: final 24-wWeek results from the phase 3b, open-label ADmirable study. Presented at: 2025 Revolutionizing Atopic Dermatitis (RAD) Conference; June 6-7, 2025; Nashville, TN.

2. Lilly's Ebglyss (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at 3 years in half of patients with moderate-to-severe atopic dermatitis. News release. Eli Lilly. March 7, 2025. Accessed June 7, 2025. 

https://investor.lilly.com/news-releases/news-release-details/lillys-ebglyssr-lebrikizumab-lbkz-single-monthly-maintenance

Lebrikizumab demonstrated efficacy and safety in treating moderate-to-severe atopic dermatitis (AD) in patients with pigmented skin, a group often underrepresented in clinical trials. The phase 3b ADmirable trial included 90 participants aged 12 and older, with significant improvements observed in Eczema Area and Severity Index (EASI) and Pruritus Numeric Rating Scale (NRS) scores by week 16, which further improved by week 24. The study reported a favorable safety profile, with most adverse effects being mild or moderate, and no serious events necessitating discontinuation of the drug.

At RAD 2025, Eli Lilly revealed promising results for lebrikizumab in treating atopic dermatitis in patients with skin of color.

Jessica Sprague, M.D.

Articles

Latest Updated Articles